Ratings Holaluz-Clidom, S.A.

Equities

HLZ

ES0105456026

Market Closed - BME Other stock markets 11:35:10 2024-04-30 am EDT			5-day change	1st Jan Change
2.57 ^EUR	+1.58%		-12.88%	-20.19%

Apr. 23	Holaluz-Clidom, S.A. announced that it expects to receive ?8 million in funding	CI
2023	Holaluz-Clidom, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company shows low valuation levels, with an enterprise value at 0.24 times its sales.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's earnings growth outlook lacks momentum and is a weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes